Sangamo BioSciences Announces New SB-728-T HIV/AIDS Data to be Presented at 51st ICAAC
RICHMOND, Calif., Sept. 8, 2011 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from all dosing cohorts of its Phase 1 study (SB-728-902) to evaluate SB-728-T for HIV/AIDS as well as preliminary data from the Phase 1 clinical study of the same drug, ongoing at the University of Pennsylvania, will be presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The meeting will be held September 17-20, 2011 in Chicago. The abstracts will be available on the ICAAC website at www.icaac.org.
Details of the presentation follow: Abst.# H1-375: "Adoptive Transfer of Zinc Finger Nuclease (ZFN) Modified Autologous CD4 T-Cells to Aviremic HIV-Infected Subjects with Suboptimal CD4 Counts" Oral Session: New Therapies for HIV and HCV, 4:00 - 6:30 p.m. CT, Saturday, September 17, 2011. Presenter: R. Mitsuyasu, M.D., Professor of Medicine, David Geffen School of Medicine at UCLA. Abst.# H2-794a: "HAART Treatment Interruption following Adoptive Transfer of Zinc Finger Nuclease (ZFN) Modified Autologous CD4 T- cells (SB-728-T) to HIV-infected Subjects Demonstrates Durable Engraftment and Suppression of Viral Load" Late-Breaker Poster Session: Antiretroviral Therapy of HIV-1 Infection, 11:15 a.m. - 1:15 p.m. CT, Sunday, September 18, 2011. Presenters: Dale Ando, M.D., Vice President, Therapeutic Development and CMO and Geoffrey Nichol, M.B., Ch.B., Executive Vice President Research and Development, Sangamo BioSciences, Inc.
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP TherapeuticÃ‚® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson’s disease, monogenic diseases, neuropathic pain and nerve regeneration. Sangamo’s core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company’s website at www.sangamo.com.
ZFP TherapeuticÃ‚® is a registered trademark of Sangamo BioSciences, Inc.
This press release may contain forward-looking statements based on Sangamo’s current expectations. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of our clinical trials, whether the clinical trials will validate and support the tolerability and efficacy of ZFNs, technological challenges, Sangamo’s ability to develop commercially viable products and technological developments by our competitors. For a more detailed discussion of these and other risks, please see Sangamo’s SEC filings, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.